Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-187-3p inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
miR-187-3p inhibitor is a synthetic antisense oligonucleotide designed to specifically target and neutralize the biological activity of microRNA-187-3p. In oncological research, miR-187-3p is recognized for its role in the miR-187-3p/FGFRL1 axis, where it typically acts as a tumor suppressor by downregulating the expression of fibroblast growth factor receptor-like 1 (FGFRL1). The inhibitor is utilized in preclinical studies to investigate competitive endogenous RNA (ceRNA) networks, such as those involving the long non-coding RNA VPS9D1-AS1, which can sponge miR-187-3p to promote cancer progression. By sequestering miR-187-3p, the inhibitor allows for the upregulation of target genes, facilitating the study of their roles in cell proliferation, migration, and invasion in diseases like prostate cancer.
- Other names
- anti-miR-187-3panti-miR187-3panti-miR 187-3pmiR-187-3p antagomirmiR187-3p antagomirmiR 187-3p antagomirhsa-miR-187-3p inhibitorhsa-miR187-3p inhibitorhsa-miR 187-3p inhibitor
Beyond the preview
Go deeper on miR-187-3p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-187-3p inhibitor.